Aclaris Therapeutics (ACRS) EBIT (2014 - 2026)

Aclaris Therapeutics' EBIT history runs 13 years deep, the most recent figure standing at -$22.2 million for Q1 2026.

• In Q1 2026, EBIT fell 22.72% year-over-year to -$22.2 million; the TTM figure through Mar 2026 stood at -$80.5 million (up 42.95% YoY), while the FY2025 annual figure was -$76.4 million, up 46.19% from the prior year.
• EBIT was -$22.2 million for Q1 2026 at Aclaris Therapeutics, up from -$22.7 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$4.0 million in Q4 2023 to a low of -$99.7 million in Q4 2024.
• Historically, EBIT has averaged -$25.2 million across 5 years, with a median of -$20.9 million in 2022.
• The sharpest annual moves came in 2023 and 2024: EBIT soared 86.08% in 2023, then sank 2362.94% in 2024.
• A 5-year view of EBIT shows it stood at -$29.1 million in 2022, then jumped by 86.08% to -$4.0 million in 2023, then tumbled by 2362.94% to -$99.7 million in 2024, then soared by 77.19% to -$22.7 million in 2025, then climbed by 2.38% to -$22.2 million in 2026.
• The last three EBIT figures came in at -$22.2 million (Q1 2026), -$22.7 million (Q4 2025), and -$17.1 million (Q3 2025), per Business Quant data.